Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti- CTLA-4 antibodies

Lax, BM; Palmeri, JR; Lutz, EA; Sheen, A; Stinson, JA; Duhamel, L; Santollani, L; Kennedy, A; Rothschilds, AM; Spranger, S; Sansom, DM; Wittrup, KD

Wittrup, KD (通讯作者)，MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.;Wittrup, KD (通讯作者)，MIT, Dept Chem Engn, Cambridge, MA 02139 USA.;Wittrup, KD (通讯作者)，MIT, Dept Biol Engn, Cambridge, MA 02139 USA.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023; 120 (31):

Abstract

Anti-CTLA- 4 antibodies have successfully elicited durable tumor regression in the clinic; however, long -term benefit is limited to a subset of patie......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索